By David Bautz, PhD NASDAQ:ICU READ THE FULL ICU RESEARCH REPORT Business Update Publication in Pediatric Nephrology Highlights Real-World QUELIMMUNE Data On February 9, 2026, SeaStar Medical Holding ...

Strong survival data extending to 90 daysReal-world experience shows results consistent with clinical trial dataFavorable safety profile – no ...

The optimal intensity of continuous renal-replacement therapy remains unclear. We conducted a multicenter, randomized trial to compare the effect of this therapy, delivered at two different levels of ...

Niigata, Japan - A new Japanese nationwide study revealed that from 2006 to 2021, the number of patients with incident renal RRT due to RPGN increased, with an increase in the age-specific incidence ...

SeaStar Medical Holding Corporation (NASDAQ:ICU) stock fell 4.8% on Monday after the company published early post-approval ...

Acute kidney injury (AKI) represents a rapid decline in renal function that poses significant clinical challenges worldwide. The syndrome is multifactorial, arising from diverse causes including ...

A UCLA-led team has developed a machine-learning model that can predict with a high degree of accuracy the short-term survival of dialysis patients on Continuous Renal Replacement Therapy (CRRT). CRRT ...

SLE flares continue to occur after ESKD in a substantial subset of patients, warranting closer monitoring. Extrarenal lupus flares continue to occur in more than one-third of patients with end-stage ...

Organ donations from the recently deceased dropped last year for the first time in over a decade, resulting in fewer kidney transplants, according to an analysis issued Wednesday that pointed to signs ...